Aa
From Specialty Pharmacy News
http://aishealth.com/sites/all/files/marketplace_pdf_samples/spn0212.pdf.
This was from Feb 2012. Interesting read. I couldn't print it because of the 8000 characters.
Have a great day!
Jules
This was from Feb 2012. Interesting read. I couldn't print it because of the 8000 characters.
Have a great day!
Jules
www.prweb.com/releases/2012/2/prweb9220211.htm
ok here we go. Go to this link and then the other link to read the article in its entirety (SP)? lol sorry guys
ok here we go. Go to this link and then the other link to read the article in its entirety (SP)? lol sorry guys
its not letting me copy this for some reason. Let me see if I can find it elsewhere
Specialty Pharmacy Reveals Early Incivek,
Victrelis Data: ‘It’s Looking Good’ for Many
When the FDA approved Incivek (telaprevir) and Victrelis (boceprevir) for the
treatment of hepatitis C last May, many in the industry hailed them as game-changers.
Not only are Merck & Co., Inc.’s Victrelis and Vertex Pharmaceuticals Inc.’s Incivek the
first oral hepatitis C therapies and the first protease inhibitors approved for the condition
(SPN 5/11, p. 1), but new data just released echo the clinical trials data that indicate
the drugs also show much more promise than the previous regimen of pegylated interferon
and ribavirin did of actually clearing the virus.
The drugs could cut the current 48-week treatment time down to 24 weeks for certain
patients if they achieve an early viral response. However, both drugs are used with
pegylated interferon and ribavirin to create a triple therapy that is fairly complicated
(SPN 9/11, p. 1). People taking Incivek stop that treatment after the initial 12 weeks and
continue the regimen only with pegylated interferon and ribavirin, while people on
Victrelis do not take it for the initial four weeks of treatment.
Patient adherence to the rigid treatment regimen is critical to the drugs’ success,
and many people are expected to clear the virus, meaning they are essentially cured.
Victrelis Data: ‘It’s Looking Good’ for Many
When the FDA approved Incivek (telaprevir) and Victrelis (boceprevir) for the
treatment of hepatitis C last May, many in the industry hailed them as game-changers.
Not only are Merck & Co., Inc.’s Victrelis and Vertex Pharmaceuticals Inc.’s Incivek the
first oral hepatitis C therapies and the first protease inhibitors approved for the condition
(SPN 5/11, p. 1), but new data just released echo the clinical trials data that indicate
the drugs also show much more promise than the previous regimen of pegylated interferon
and ribavirin did of actually clearing the virus.
The drugs could cut the current 48-week treatment time down to 24 weeks for certain
patients if they achieve an early viral response. However, both drugs are used with
pegylated interferon and ribavirin to create a triple therapy that is fairly complicated
(SPN 9/11, p. 1). People taking Incivek stop that treatment after the initial 12 weeks and
continue the regimen only with pegylated interferon and ribavirin, while people on
Victrelis do not take it for the initial four weeks of treatment.
Patient adherence to the rigid treatment regimen is critical to the drugs’ success,
and many people are expected to clear the virus, meaning they are essentially cured.
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
